Coronavirus
The Novavax Vaccine Appears to Be Highly Effective in Trial Studies
Novavax on Monday revealed the results of a phase three COVID-19 vaccine trial that determined that the company’s two-dose inoculation is highly effective.
The trial, in which 29,960 participants were enrolled across 119 states in the U.S. and Mexico, found the Novavax vaccine to be 90.4 percent effective overall, and 100 percent effective in protecting against moderate and severe disease.
The vaccine was also found to be 91 percent effective among high-risk populations, defined as individuals over the age of 65, or younger if they have certain comorbidities.
